Meta-analysis compares safety profiles of ranibizumab intravitreal injections

TORONTO — Safety profiles of intravitreal ranibizumab injections were shown to be consistent with the established systemic safety profile of ranibizumab, according to a presenter here. “Intravitreally, there are concerns about the possibility of systemic adverse events, but we haven’t really been able to calculate accurately because of sample size,” Baruch D. Kuppermann, MD, told colleagues at the American Society of Retina Specialists meeting here. To overcome that barrier, a pairwise comparison of 14 phase 2/3 randomized clinical trials was undertaken, looking in particular for serious adverse events occurring after (Read more...)

Full Story →